A5003919808- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Protein Tyrosine Phosphatases
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Computational Drug Discovery Methods
- Cancer Mechanisms and Therapy
- Virus-based gene therapy research
- Infectious Diseases and Mycology
- Drug-Induced Adverse Reactions
- Monoclonal and Polyclonal Antibodies Research
- Chemotherapy-related skin toxicity
- Dermatological diseases and infestations
- Pluripotent Stem Cells Research
- Dermatological and Skeletal Disorders
- Cancer-related gene regulation
Centre Hospitalier Universitaire de Nantes
2021-2024
Nantes Université
2023-2024
Inserm
2011-2024
Immunologie et Nouveaux Concepts en Immunothérapie
2021-2023
Cleveland Clinic
2023
Hôtel-Dieu de Paris
2022
Hôpital Pontchaillou
2016-2021
Centre Hospitalier Universitaire de Rennes
2017-2021
Institut de génétique et de développement de Rennes
2016-2021
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2021
Vitiligo is an autoimmune skin disorder that reacts against melanocytes. The association of vitiligo with tumor response in patients melanoma who undergo immunotherapy has been reported but still controversial.To prospectively evaluate the appearance receiving pembrolizumab, a monoclonal antibody directed programmed death cell receptor.This prospective observational study was conducted from January 1, 2012, through September 24, 2013, single tertiary care hospital unit dedicated to melanoma....
Target cell tropism of enveloped viruses is regulated by interactions between viral and cellular factors during transmission, dissemination, replication within the host. Binding envelope glycoproteins to specific cell-surface receptors determines susceptibility entry. However, a number molecules bind without mediating Instead, they serve as capture that disseminate particles target organs or susceptible cells. We others recently demonstrated C type lectins L-SIGN DC-SIGN hepatitis virus...
Abstract Purpose: The emergence of skin tumors in patients treated with sorafenib or more recent BRAF inhibitors is an intriguing and potentially serious event. We carried out a clinical, pathologic, molecular study lesions occurring receiving sorafenib. Experimental Design: Thirty-one from were characterized clinically pathologically. DNA extracted the was screened for mutation hot spots HRAS, NRAS, KiRAS, TP53, EGFR, BRAF, AKT1, PI3KCA, TGFBR1, PTEN. Biological effect studied vivo normal...
The BRAF inhibitor, vemurafenib, was recently approved for the treatment of patients with BRAFV600 metastatic melanoma. Wider use this drug and longer follow-up periods are resulting in emergence a growing number reports detailing new adverse effects. Cutaneous effects preeminent UV-A-dependent phototoxicity, hyperkeratotic folliculitis, hand-foot skin reaction, hair changes, verrucous papillomas, keratoacanthomas, squamous cell carcinomas.We report 2 cases dermatitis occurring on previously...
<i>Background:</i> Anti-tumor necrosis factor (TNF) agents are increasingly being used for a rapidly expanding number of rheumatic and systemic diseases. As result this use, the longer follow-up periods treatment, there growing reports development autoimmune processes related to anti-TNF agents. The use has been associated with more cases diseases, principally cutaneous vasculitis, lupus-like syndrome, lupus erythematosus interstitial lung disease....
BRAF inhibitors (BRAFi) elicit therapeutic responses in metastatic melanoma, but alarmingly, also induce the formation of secondary benign and malignant skin tumors. Here, we report emergence molecular characterization 73 extracutaneous tumors 31 patients who underwent BRAFi therapy. The majority presented with classic epidermal such as verrucous papillomas, keratoacanthomas, squamous cell carcinomas (SCC). However, 15 exhibited new or rapidly progressing distinct from these subtypes, lymph...
Treatment with RAF inhibitors such as vemurafenib causes the development of cutaneous squamous cell carcinomas (cSCC) or keratoacanthomas a side effect in 18% to 30% patients. It is known that activate mitogen-activated protein kinase (MAPK) pathway and stimulate growth RAS-mutated cells, possibly accounting for up 60% cSCC keratoacanthoma lesions RAS mutations, but other contributing events are obscure. To identify events, we evaluated tumors from patients treated presence human papilloma...
Pathogenic variants (PV) of CTNNA1 are found in families fulfilling criteria for hereditary diffuse gastric cancer (HDGC) but no risk estimates were available until now. The aim this study is to evaluate (DGC) risks carriers germline PV.Data from published updated and new identified through international collaborations. cumulative DGC by age PV was estimated with the genotype restricted likelihood (GRL) method, taking into account non-genotyped individuals conditioning on all observed...
The tumor mutational burden (TMB) is high in melanomas owing to UV-induced oncogenesis. While a TMB predictive biomarker of response PD-1 inhibitors, it may be associated with the rise resistant clones targeted therapy over time. We hypothesized that survivals depend on both sun-exposure profile site primary melanoma and type systemic treatment.
Abstract Lithium is potent non‐competitive inhibitor of an enzyme involved in the metabolism phosphatidylinositol 4,5‐bisphosphate (PtdIns‐4,5‐P 2 ), a critical phosphoinositide (PI) that regulates signal transduction and synaptic vesicle function. Interestingly, number genes regulation PtdIns‐4,5‐P synthesis dephosphorylation are found regions genome previously mapped bipolar disorder (BPD) including 10p, 18q, 21q, 22q. One PIK4CA , member 4‐kinase family phosphorylates PtdIns at D4...
Activating BRAFV600E mutations occur in about 43% of primary melanomas [1]. An early clinical experience with a novel class I RAF-selective inhibitor, vemurafenib, demonstrated an unprecedented 48% antitumor response rate among patients BRAFV600E-positive [2].Although vemurafenib sensitizes melanoma cells to irradiation vitro [3], it has never been tested combined radiotherapy trial. We report dramatic responses two who exhibited [...]
TPS9114^ Background: Both D and T have demonstrated clinical activity as monotherapies in combination BRAF mutation–positive melanoma. However, the mechanism of acquired drug resistance toxicity are not fully understood. We plan to investigate sequential effects MEK inhibition on skin, blood, tumor biomarkers, well study correlations between biomarkers response treatment toxicity. Methods: This is a 3-arm, open-label, randomized, phase 2 biomarker France, comparing upfront with versus their...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Abstract INTRODUCTION : BRAF inhibitors (BRAFI) are affective anti-melanoma agents in V600BRAF mutant melanoma but have one major adverse event, the paradoxical activation of MAPK pathway WT cells, which favors emergence benign, borderline and malignant skin cancers: verrucous papillomas, kératoacanthomas (KA), squamous cell carcinomas (SCC) even new melanomas. MATERIALS AND METHODS Between January 2010 October 2013 we collected 63 tumors, 1 vulvar tumor, gingival urothelial tumor 50...